Showing results (1-10 of 77) with videos related to
Sort By:
Pageof 8
European Journal of Haematology|June 20, 2020
Evolution of diagnostic workup and treatment for multiple myeloma 2013-2019Fredrik SchjesvoldCancers|June 2, 2021
Current and Novel Alkylators in Multiple MyelomaFredrik Schjesvold, Albert OriolJournal of Bone Oncology|April 17, 2025
Treatment of myeloma bone disease: When, how often, and for how long?Michael Tveden Gundesen, Fredrik Schjesvold, Thomas LundFrontiers in Immunology|August 20, 2024
Advances and challenges in anti-cancer vaccines for multiple myelomaPegah Abdollahi, Hanne Marie Norseth, Fredrik SchjesvoldFuture Oncology (London, England)|March 7, 2020
OCEAN: a randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myelomaFredrik Schjesvold, Pawel Robak, Ludek Pour, et al.Cancer Research|June 4, 2015
Tumors Escape CD4+ T-cell-Mediated Immunosurveillance by Impairing the Ability of Infiltrating Macrophages to Indirectly Present Tumor AntigensAnders Aune Tveita, Fredrik Schjesvold, Ole Audun Haabeth, et al.Ejhaem|November 29, 2023
Difficult-to-treat patients with relapsed/refractory multiple myeloma: A review of clinical trial resultsMarc S Raab, Elena Zamagni, Salomon Manier, et al.European Journal of Haematology|February 3, 2022
A prospective study of Skeletal survey versus Low-dose whole-body CT for Osteolytic lesions in Multiple MyelomaMichael T Gundesen, Jon T Asmussen, Einar Haukås, et al.Molecular Imaging and Biology|May 2, 2022
Comparison of [18F]fluciclovine and [18F]FDG PET/CT in Newly Diagnosed Multiple Myeloma PatientsCaroline Stokke, Jakob Nordberg Nørgaard, Hilde Feiring Phillips, et al.Expert Review of Clinical Pharmacology|June 20, 2022
Melflufen for the treatment of multiple myelomaEnrique M Ocio, Omar Nadeem, Fredrik Schjesvold, et al.Pageof 8